Navigation Links
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
Date:3/20/2008

- By targeting interleukin-6 receptors, ACTEMRA provides significant

benefits for patients when compared with existing therapies -

NUTLEY, N.J., March 20 /PRNewswire/ -- Patients with rheumatoid arthritis treated with Roche's ACTEMRA(TM) (tocilizumab) experienced significant and rapid reduction in the signs and symptoms of their disease, according to a study published in this week's issue of The Lancet. Results from the OPTION (TOcilizumab Pivotal Trial in Methotrexate Inadequate respONders) trial -- a Phase III international study -- demonstrated that RA patients achieved greater improvement of symptoms and a higher quality-of-life with ACTEMRA, an interleukin-6 (IL-6) receptor inhibitor, in combination with methotrexate, compared with methotrexate plus placebo.

"Results of this pivotal study convincingly demonstrate that tocilizumab can effectively and rapidly diminish the painful and debilitating effects of rheumatoid arthritis," said Josef Smolen, M.D., lead investigator of the OPTION trial and Professor of Medicine at the Department of Internal Medicine at the Medical University of Vienna, Austria. "These trial findings are significant because we know that many rheumatoid arthritis patients continue to experience symptoms of joint pain, stiffness, physical disability and fatigue, despite treatment with existing therapies."

About OPTION Study

In the OPTION trial, a three-arm, double-blind, controlled Phase III study, 623 patients were randomized to receive ACTEMRA intravenously (either 4mg/kg or 8mg/kg) every four weeks plus methotrexate weekly or placebo infusions plus methotrexate weekly. The study was conducted in 73 trial sites in 17 countries outside the United States.

At 24 weeks, 58.5% of ACTEMRA patients (8mg/kg) achieved a 20% reduction in RA symptoms (ACR20)(1), compared with 26.5% of patients in placebo plus methotrexate patients. In the study, 43.9% of patients treated with ACTEMRA (8mg/kg) plus meth
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)STREAMWOOD, Ill., Dec. 4 Shared Imaging, LLC, an independent provider of CT, MRI and PET/CT systems and service programs for hospitals and healthcare providers, is excited to announce it has received
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is prese
(Date:12/4/2009)TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced the three grand prize winners of Bayer,s "Express Your Simple Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the winn
Breaking Medicine Technology:Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3New Lumension Endpoint Management and Security Suite To Deliver End to End Endpoint Management Capabilities 62352 1New Lumension Endpoint Management and Security Suite To Deliver End to End Endpoint Management Capabilities 62352 2New Lumension Endpoint Management and Security Suite To Deliver End to End Endpoint Management Capabilities 62352 3New Lumension Endpoint Management and Security Suite To Deliver End to End Endpoint Management Capabilities 62352 4New Lumension Endpoint Management and Security Suite To Deliver End to End Endpoint Management Capabilities 62352 5New Lumension Endpoint Management and Security Suite To Deliver End to End Endpoint Management Capabilities 62352 6Hobby Lobby Selects Concentra to Open Health Center 62350 1Hobby Lobby Selects Concentra to Open Health Center 62350 2Hobby Lobby Selects Concentra to Open Health Center 62350 3US Farms Inc Announces Marketing Agreement With Micro Lending Institution Angels In Action 62347 1US Farms Inc Announces Marketing Agreement With Micro Lending Institution Angels In Action 62347 2US Farms Inc Announces Marketing Agreement With Micro Lending Institution Angels In Action 62347 3
...eague,s historic Personhood Conference is featurin...earch and regenerative medicine. , , (Logo: htt...OGO ) , , Dr. Theresa Deisher, founder and CEO o...Pharmaceutical Institute, is speaking on over 17 y...ry, production and commercialization of human ther...
...x Foundation for Parkinson,s Research awarded abou... will test drugs already approved in other disease...son,s disease. Because both drugs being tested are...tential to move swiftly toward regulatory approval...ective in PD. , , One funded team will investigat...
Other Medicine Technology:Stem Cell Pioneer to Speak to A.L.L. Personhood Conference 2Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinson's Disease Clinical Trials 2
(Date:12/5/2009)Research debunks the ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the poor single people who pass their 40th birthday without ever tying the knot, s
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
Breaking Medicine News(10 mins):Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2
...S Board, TORONTO, April 21 /PRNewswire-FirstCall/...der of products and services to the global life,sc...pivy, Partner at,ValueAct Capital, and Mr. William...look forward to benefiting from the,breadth of exp...
...lp or neck appear less likely to survive for five ...s, according to a report in the April issue of Arc...rnals. , Melanoma rates continue to increase whil...rognosis has been debated for decades, the authors...
...ing focus on hospital-physician ... /PRNewswire/ - The Deloitte Forensic Center repor...tions continues to get more,complex for hospitals...., that hospitals or the physicians,they enter into...
...ouncil is pleased to announce that the winner of t...Human Rights is Dr. Binayak Sen of Raipur,Chhattis...sh a hospital serving poor mine,workers in the reg...r nearly a year without trial as a result of,alleg...
...ncies diagnosed on face, ears, study finds , ... deadly melanoma skin cancers occur on the scalp a...apel Hill (UNC) study. , Researchers analyzed 51,7...where on the body, including the face or ears. , T...
...tion, BIRMINGHAM, Ala., April 21 Surgical Care A...ayek has been named president and,chief executive ...dent and,chief executive officer, Mike Snow, is re... served as president of VillageHealth Inc., an,ins...
Other Medicine News:Health News:MDS Appoints Two New Directors 2Health News:MDS Appoints Two New Directors 3Health News:Survival rates appear lower for scalp and neck melanoma than for other sites 2Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 2Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 3Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 4Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 5Health News:Jailed Indian Pediatrician Wins 2008 Jonathan Mann Award for Global Health and Human Rights 2Health News:Jailed Indian Pediatrician Wins 2008 Jonathan Mann Award for Global Health and Human Rights 3Health News:Melanomas on Scalp and Neck More Deadly 2Health News:SCA Names Andrew Hayek as New President and CEO 2
... Orthosis Until now, laborious custom fabrication ...tability was limited and modifications in response...d cumbersome.,The GunSlinger evolved from two yea...ching hospital. This orthosis can be quickly adjus...
...gned for the functional management of grade I, II,...e-inflated aircell, the brace provides focused, pn... while supporting the arm and shoulder. A detachab...additional arm support and helps to unload the wai...
...to treat or help prevent lower extremity disorder..., foot drop, contractures and pressure necrosis at...s a comfortable wicking interface for the patient....ed into a vertical configuration when not needed o...
... ankle. This simple concept is the cornerstone of ... you lock the heel with our patent-pending Stablel...d comfort your patient will experience walking in ...the heel and supports the posterior aspect of the ...
Medicine Products: